LOS ANGELES, CA--(Marketwire - August 13, 2009) - BioMedReports, the leading news portal covering the publicly traded biomedical and pharmaceutical companies of the financial markets, in a special report about stem cell banking has reported that CRYO-CELL International (OTCBB: CCEL) may have quietly positioned itself as one of the stem cell sector’s first truly profitable companies by principally engaging in the collection and preservation of umbilical cord (U-Cord) blood stem cells for family use.
Currently the company is also involved in the development of various new technologies in the stem cell arena which many consider to be leading wave in future medicine. The Company has established itself as a leader in cord blood stem cell banking and it handles business operations, including the processing and storage of specimens in its state-of-the-art cryogenic storage units and it has also developed C’elle, a technology related to menstrual stem cells.
“It’s clear to see how the services and products this company provides will become increasingly important and valuable,” says M.E. Garza, who writes for BioMedReports. “And unlike other companies in the same space, they are forming solid partnerships, getting involved in key research to develop new products and technologies with their state of the art facilities and a great looking balance sheet.”
The company and its founders pioneered ways to make it affordable for everybody to store their own Umbilical blood cells and they quickly became the only product endorsed by Lamaze. They’ve experienced a big push with hospitals and doctors and are attracting more interest from Wall Street.
The new special report about the company appears now at BioMedReports.com:
Biotech investors interested in accessing the complete database of clinical trials and upcoming FDA decisions can access that information on the same site:
Contact:
Mike Havrilla
Managing Editor
BioMedReports.Com
Email Contact
323-472-4480 Phone
888-210-3556 Fax
